ALN-VSP Data at 2011 ASCO Meeting

ALN-VSP Data at 2011 ASCO Meeting

At the ASCO Annual Meeting in June 2011, we presented complete results from our Phase I clinical trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of patients with advanced solid tumors with liver involvement.





Data presented showed that ALN-VSP was generally well tolerated and showed evidence for anti-tumor activity.  Importantly, ALN-VSP was found to mediate RNAi activity in both hepatic and extra-hepatic tumors.  We are very encouraged by these results, as they represent an important milestone in the advancement of RNAi therapeutics – showing for the first time both clinical activity and  proof of the RNAi mechanism in man with an RNAi therapeutic.



SIGN UP FOR PATIENT CONNECT

Receive updates on our investigational therapies and clinical trials.